Insitro completed its full stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and other complex biologics with an integrated approach that accelerates the generation of clinic-ready assets while reducing late-stage development risk. The company applies its approach to identify genetic drivers, prioritize targets, and design medicines intended to treat disease at its root, with programs focused in metabolic disease and neuroscience.
Cyborg Score Rationale
Insitro has raised approximately $800M in capital, including approximately $150M from non-dilutive pharma partnerships, demonstrating strong market validation and strategic pharma alignment. As of May 31, 2026, the latest employee count at Insitro is 254, showing measured growth. The acquisition of CombinAbleAI in January 2026 completed its AI platform for drug discovery and design, enabling a differentiated full-stack capability.
Top Insights
In January 2026, Insitro acquired CombinAbleAI and launched its TherML platform, completing full-stack, modality-agnostic capability spanning small molecules, oligonucleotides, antibodies, and complex biologics.
Insitro received $25 million in milestone payments from Bristol Myers Squibb for the achievement of discovery milestones and the selection of first novel genetic target for ALS.
Insitro ranks 5th amongst 671 active competitors, of which 247 are funded, and stands 1st in terms of total funding among its competitors.
The CombinAbleAI team will continue to operate in Israel as a new Insitro R&D center focused on advancing large molecule design.
Named Competitors
Exscientia — AI-driven drug discovery platform
Recursion Pharmaceuticals — Machine learning-enabled drug discovery